Investor Relations: TSXV: NRX >
April 10, 2025
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
April 4, 2025
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
March 16, 2025
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
February 16, 2025
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
February 6, 2025
NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
Investor Relations: TSXV: NRX > ExoPTEN has been granted Orphan Drug Designation (“ODD”) by the FDA indicating the priority of developing therapies for acute SCI conditions. ODD is expected to streamline regulatory and clinical process

Drug Delivery by Exosome

Where Nature Ends, NurExone Begins

Exosome based therapies

Potential and Benefits

NurExone chose to base its ultimate drug delivery platform on exosomes-nanosized extracellular vesicles-due to their natural ability to reach inflamed or damaged tissue. By loading exosomes with therapeutic compounds, nanodrugs are created having natural regenerative properties and therapeutic impact.

Non-Invasive​

Off the shelf targeted medicine

Cell-free

Crosses the
Blood Brain Barrier

Regenerate, Rewire, Recover

First product from the ExoTherapy platform
ExoPTEN for acute spinal cord injury

MRI images of laboratory rats

WATCH THE STUDY
ExoPTEN, an siRNA sequence loaded onto exosomes, has been proven to regenerate and rewire neurons in lab animals with fully transected spinal cords

2.9B Global market for acute spinal cord injury by 2027*

75% of lab animals recovered motor function and bladder control following short treatment with ExoPTEN administered intranasally.

2023 ExoPTEN received FDA Orphan Drug Designation and
first-in-human expected in 2025.

NurExone ExoTherapy Platform

for Noninvasive Nanodrugs

Exosome
The company’s dedicated in-house bioreactor produces potent exosomes with high quality and large scale using proprietary 2D and 3D production processes.
Active Pharmaceutical Ingredient (API)
The company’s team of biologists and PhDs sysnthesizes compounds with therapeutic properties and active pharmaceutical ingredients
Nanodrug
Nanodrugs are created by loading the therapeutic compound onto exosomes (short peptides, molecules). Known APIs can be repurposed and loaded onto the exosomes under a proprietary loading process.

Where nature ends, NurExone begins

As we unharness the power of exosomes to push the edge of medicine and biology, our ExoTherapy platform technology for producing and loading quality exosomes will incorporate new, exciting technologies and IP that may be licensed and spun off for other applications, and indications, driving early revenues and creating value for shareholders.

Join our journey

THE 50 Top-Performing Companies ON TSX VENTURE EXCHANGE

ABOUT

Technology

Contact Us

Copyright © 2025 All rights reserved to NurExone

Set layout popup